izpis_h1_title_alt

Določanje alelne frekvence polimorfizmov farmakogena NUDT15 v slovenski populaciji
ID Kastelic, Helena (Avtor), ID Karas Kuželički, Nataša (Mentor) Več o mentorju... Povezava se odpre v novem oknu, ID Urbančič, Dunja (Komentor)

.pdfPDF - Predstavitvena datoteka, prenos (1,86 MB)
MD5: 0C63894AC593F8D25953EA85354E5255

Izvleček
Akutna limfoblastna levkemija (ALL) je bolezen, pri kateri pride do nenormalnega razraščanja nezrelih celic limfocitne vrste (limfoblastov). Za njeno zdravljenje se uporabljajo tiopurini, učinkovine z imunosupresivnim in citostatičnim delovanjem, med katere sodijo 6-tiogvanin (6-TG), 6-merkaptopurin (6-MP) in azatioprin (AZA). Pri odzivu na zdravljenje z njimi imajo pomembno vlogo polimorfizmi v genu za nudiks hidrolazo 15 (NUDT15), ki lahko vodijo v njihovo večjo toksičnost. Želeli smo ugotoviti frekvence polimorfizmov v genu NUDT15 (rs61746486, rs45465203, rs61973267, rs116855232), ki smo jih predhodno identificirali pri bolnikih zdravljenih s tiopurini, in jih preko določitve vrednosti MAF opredeliti kot farmakogenetske diagnostične kazalce v slovenski populaciji. Preverili smo njihovo skladnost s frekvencami v drugih populacijah in izračunali, ali se v slovenski populaciji nahajajo v Hardy-Weinbergovem ravnovesju. Identificirali smo tudi druge polimorfizme v kodirajočih regijah NUDT15. Raziskali smo, ali napovedni bioinformacijski modeli predpostavljajo vključenost identificiranih polimorfizmov pri odzivu na zdravljenje s tiopurini. Iz krvi zdravih preiskovancev smo izolirali DNA in preverili njeno kakovost. Izvedli smo verižno reakcijo s polimerazo (ang. polimerase chain reaction, PCR) ter ekson 1 in ekson 3 z okolico sekvencirali po Sangerju. Z uporabo bioinformacijskih orodij smo preverili frekvence teh polimorfizmov v drugih populacijah ter vrednotili njihove posledice na funkcijo proteinskega produkta NUDT15. Iz rezultatov lahko sklenemo, da bi bilo pred začetkom zdravljenja smiselno določanje polimorfizmov rs45465203 in rs61973267. Frekvenci polimorfizmov rs45465203 in rs61973267 sta v slovenski populaciji nižji kot v evropski in višji kot v vzhodnoazijski in afriški. Polimorfizma rs61746486 in rs116855232 sta v slovenski populaciji bolj razširjena kot v evropski, vendar je frekvenca polimorfizma rs116855232 bistveno višja med prebivalci azijskih držav. Izračunali smo, da so populacije vseh preiskovanih polimorfizmov v Hardy-Weinbergovem ravnovesju. Dodatno smo identificirali polimorfizma rs79687000 in rs1249937565, ki pa jih zaradi pomanjkanja podatkov o populacijski genetiki nismo mogli primerjati z drugimi populacijami. Z uporabo napovednih modelov smo ugotovili, da bi polimorfizmi rs45465203, rs79687000, rs124937565 in rs61973267 potencialno lahko vplivali na funkcijo proteina. Vpeljava polimorfizma rs116855232 v diagnostični panel pa bi bila kljub nizki vrednosti MAF v slovenski populaciji smiselna zaradi njegove navedbe v CPIC priporočilih.

Jezik:Slovenski jezik
Ključne besede:Nudiks hidrolaza 15 (NUDT15), Polimorfizem, Tiopurini, Akutna limfoblastna levkemija (ALL), Farmakogen
Vrsta gradiva:Magistrsko delo/naloga
Organizacija:FFA - Fakulteta za farmacijo
Leto izida:2024
PID:20.500.12556/RUL-156162 Povezava se odpre v novem oknu
Datum objave v RUL:11.05.2024
Število ogledov:103
Število prenosov:33
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Sekundarni jezik

Jezik:Angleški jezik
Naslov:Determination of allelic frequency of pharmacogene NUDT15 polymorphisms in the Slovenian population
Izvleček:
Acute lymphoblastic leukemia (ALL) leads to the abnormally high proliferation of immature lymphocytes (lymphoblasts). ALL treatment includes immunosuppressive and cytostatic agents called thiopurines (6-thioguanine (6-TG), 6-mercaptopurine (6-MP) and azathioprine (AZA)). Nudix hydrolase 15 (encoded by NUDT15) plays an important role in their metabolism is, thus variations in NUDT15 modulate the toxicity of thiopurines. We wanted to determine the frequencies of previously determined polymorphisms (rs61746486, rs45465203, rs61973267, rs116855232) in Slovenian population and investigate their usefulness as pharmacogenetic diagnostic markers by calculating their MAF value. We compared their frequencies between Slovenian and other populations and calculated whether they were in Hardy – Weinberg equilibrium in the investigated Slovenian population. We also identified other polymorphisms in the coding regions of NUDT15. We checked if the bioinformatic models predicted their involvement in the response to thiopurine treatment. We isolated DNA from the blood of healthy individuals and checked its quality. We performed a polymerase chain reaction (PCR) and Sanger sequencing of exons 1 and 3, including the surrounding regions. We checked the frequency of these genetic polymorphisms in other populations using bioinformatics tools and evaluated their effect on NUDT15 protein product. We determined that polymorphisms rs45465203 in rs61973267 may be useful as pharmacogenomic markers, due to the appropriate MAF value. The frequencies of rs45465203 and rs61973267 in the Slovenian population are lower than in the European and higher than in the East Asian and African populations. In contrast, rs61746486 and rs116855232 polymorphisms are more widespread in the Slovenian population than in other European populations, but the frequency of the rs116855232 polymorphism is significantly higher among Asians. We determined that all of the investigated polymorphisms are in Hardy-Weinberg equilibrium. We also found two additional polymorphisms rs79687000 and rs1249937565 in NUDT15, whose frequencies cannot be compared due to the lack of data on population genetics. Using predictive models, we found that rs45465203, rs79687000, rs124937565 and rs61973267 polymorphisms could potentially affect protein function. The use of the rs116855232 polymorphism in the diagnostic panel would, despite its low MAF value in the Slovenian population, make sense due to its involvement in the CPIC recommendations.

Ključne besede:Nudix hydrolase 15 (NUDT15), Polymorphism, Thiopurines, Acute lymphoblastic leukemia (ALL), Pharmacogene

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj